The emergence of SARS-CoV-2 variants harboring mutations in the spike (S) protein has
raised concern about potential immune escape. Here, we studied humoral and cellular …

The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
had a large impact on global health, travel, and economy. Therefore, preventative and …

A desirable but as yet unachieved property of a human immunodeficiency virus type 1 (HIV-1)
vaccine candidate is the ability to induce broadly neutralizing antibodies (bNAbs). One …

HIV-1 entry into CD4 + target cells is mediated by cleaved envelope glycoprotein (Env)
trimers that have been challenging to characterize structurally. Here, we describe the crystal …

Background Limb salvage for severe trauma has replaced amputation as the primary
treatment in many trauma centers. However, long-term outcomes after limb reconstruction or …

The HIV envelope (Env) protein gp120 is protected from antibody recognition by a dense
glycan shield. However, several of the recently identified PGT broadly neutralizing antibodies …

Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. …

The HIV-1 envelope glycoprotein (Env) trimer contains the receptor binding sites and membrane
fusion machinery that introduce the viral genome into the host cell. As the only target for …

Antibodies capable of neutralizing HIV-1 often target variable regions 1 and 2 (V1V2) of the
HIV-1 envelope, but the mechanism of their elicitation has been unclear. Here we define the …

We have analyzed the unique epitope for the broadly neutralizing human monoclonal antibody
(MAb) 2G12 on the gp120 surface glycoprotein of human immunodeficiency virus type 1 (…